Nodal promotes invasive phenotypes via a mitogen-activated protein kinase-dependent pathway

Oncogene

Volumn 33, Issue 4, 2014, Pages 461-473

  Quail, D F ^a   Zhang, G ^a,c   Findlay, S D ^a,c   Hess, D A ^b,c   Postovit, L M ^a,c  

^a WESTERN UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Cancer; EMT; Invasion; Metastasis; Nodal

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; DOXYCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NERVE CELL ADHESION MOLECULE; PROTEIN NODAL; SHORT HAIRPIN RNA; SMAD PROTEIN; TRANSCRIPTION FACTOR TWIST; UVOMORULIN; VIMENTIN; NODAL PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER SIZE; CARCINOMA CELL; CELL INVASION; CELL MIGRATION; CELL STRAIN MCF 7; CHORIOCARCINOMA; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIVER METASTASIS; LOSS OF FUNCTION MUTATION; LUNG METASTASIS; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR INVASION; ANIMAL; CELL MOTION; CELL SURVIVAL; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSFECTION; METABOLISM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; EPITHELIAL-MESENCHYMAL TRANSITION; FLUORESCENT ANTIBODY TECHNIQUE; HETEROGRAFTS; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; NEOPLASM INVASIVENESS; NODAL PROTEIN; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 84897020005     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.608     Document Type: Article

References (47)

1. Drasin DJ, Robin TP, Ford HL. Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity. Breast Cancer Res 2011; 13: 226.
2. Vicovac L, Aplin JD. Epithelial-mesenchymal transition during trophoblast differentiation. Acta Anat (Basel) 1996; 156: 202-216.
3. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40: 499-507.
4. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
5. Hendrix MJ, Seftor EA, Seftor RE, Kasemeier-Kulesa J, Kulesa PM, Postovit LM. Reprogramming metastatic tumour cells with embryonic microenvironments. Nat Rev Cancer 2007; 7: 246-255.
6. Strizzi L, Hardy KM, Kirsammer GT, Gerami P, Hendrix MJ. Embryonic signaling in melanoma: potential for diagnosis and therapy. Lab Invest 2011; 91: 819-824.
7. Strizzi L, Postovit LM, Margaryan NV, Seftor EA, Abbott DE, Seftor RE et al. Emerging roles of nodal and Cripto-1: from embryogenesis to breast cancer progression. Breast Dis 2008; 29: 91-103.
8. Roberts HJ, Hu S, Qiu Q, Leung PC, Caniggia I, Gruslin A et al. Identification of novel isoforms of activin receptor-like kinase 7 (ALK7) generated by alternative splicing and expression of ALK7 and its ligand, Nodal, in human placenta. Biol Reprod 2003; 68: 1719-1726.
9. Lawrence MG, Margaryan NV, Loessner D, Collins A, Kerr KM, Turner M et al. Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells. Prostate 2011; 71: 1198-1209.
10. Lee CC, Jan HJ, Lai JH, Ma HI, Hueng DY, Gladys Lee YC et al. Nodal promotes growth and invasion in human gliomas. Oncogene 2010; 29: 3110-3223.
11. Topczewska JM, Postovit LM, Margaryan NV, Sam A, Hess AR, Wheaton WW et al. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med 2006; 12: 925-932.
12. Postovit LM, Seftor EA, Seftor RE, Hendrix MJ. Targeting Nodal in malignant melanoma cells. Expert Opin Ther Targets 2007; 11: 497-505.
13. Postovit LM, Margaryan NV, Seftor EA, Kirschmann DA, Lipavsky A, Wheaton WW et al. Human embryonic stem cell microenvironment suppresses the tumori- genic phenotype of aggressive cancer cells. Proc Natl Acad Sci USA 2008; 105: 4329-4334.
14. Strizzi L, Postovit LM, Margaryan NV, Lipavsky A, Gadiot J, Blank C et al. Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention. Expert Rev Dermatol 2009; 4: 67-78.
15. Papageorgiou I, Nicholls PK, Wang F, Lackmann M, Makanji Y, Salamonsen LA et al. Expression of nodal signaling components in cycling human endometrium and in endometrial cancer. Reprod Biol Endocrinol 2009; 7: 122.
16. Lonardo E, Hermann PC, Mueller MT, Huber S, Balic A, Miranda-Lorenzo I et al. Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell 2011; 9: 433-446.
17. Cavallari C, Fonsato V, Herrera MB, Bruno S, Tetta C, Camussi G. Role of Lefty in the anti tumor activity of human adult liver stem cells. Oncogene 2013; 32: 819-826.
18. Munir S, Xu G, Wu Y, Yang B, Lala PK, Peng C. Nodal and ALK7 inhibit proliferation and induce apoptosis in human trophoblast cells. J Biol Chem 2004; 279: 31277-31286.
19. Nadeem L, Munir S, Fu G, Dunk C, Baczyk D, Caniggia I et al. Nodal signals through activin receptor-like kinase 7 to inhibit trophoblast migration and invasion: implication in the pathogenesis of preeclampsia. Am J Pathol 2011; 178: 1177-1189.
20. Strizzi L, Hardy KM, Margaryan NV, Hillman DW, Seftor EA, Chen B et al. Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer. Breast Cancer Res 2012; 14: R75.
21. Quail DF, Walsh LA, Zhang G, Findlay SD, Moreno J, Fung L et al. Embryonic protein Nodal promotes breast cancer vascularization. Cancer Res 2012; 72: 3851-3863.
22. Schier AF. Nodal signaling in vertebrate development. Annu Rev Cell Dev Biol 2003; 19: 589-621.
23. Beck S, Le Good JA, Guzman M, Ben HN, Roy K, Beermann F et al. Extraembryonic proteases regulate Nodal signaling during gastrulation. Nat Cell Biol 2002; 4: 981-985.
24. Clements M, Pernaute B, Vella F, Rodriguez TA. Crosstalk between Nodal/activin and MAPK p38 signaling is essential for anterior-posterior axis specification. Curr Biol 2011; 21: 1289-1295.
25. Lee MK, Pardoux C, Hall MC, Lee PS, Warburton D, Qing J et al. TGF-beta activates Erk MAP kinase signaling through direct phosphorylation of ShcA. EMBO J 2007; 26: 3957-3967.
26. Davies M, Robinson M, Smith E, Huntley S, Prime S, Paterson I. Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-beta1 involves MAPK, Smad and AP-1 signaling pathways. J Cell Biochem 2005; 95: 918-931.
27. Chakraborty C, Gleeson LM, McKinnon T, Lala PK. Regulation of human trophoblast migration and invasiveness. Can J Physiol Pharmacol 2002; 80: 116-124.
28. Quail DF, Taylor MJ, Walsh LA, Dieters-Castator D, Das P, Jewer M et al. Low oxygen levels induce the expression of the embryonic morphogen Nodal. Mol Biol Cell 2011; 22: 4809-4821.
29. Quail DF, Maciel TJ, Rogers K, Postovit LM. A unique 3D in vitro cellular invasion assay. J Biomol Screen 2012; 17: 1088-1095.
30. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927-939.
31. Scherbakov AM, Andreeva OE, Shatskaya VA, Krasil'nikov MA. The relationships between snail1 and estrogen receptor signaling in breast cancer cells. J Cell Biochem 2012; 113: 2147-2155.
32. Dhasarathy A, Kajita M, Wade PA. The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha. Mol Endocrinol 2007; 21: 2907-2918.
33. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
34. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002; 62: 65-74.
35. Postovit LM, Margaryan NV, Seftor EA, Hendrix MJ. Role of nodal signaling and the microenvironment underlying melanoma plasticity. Pigment Cell Melanoma Res 2008; 21: 348-357.
36. Taylor MA, Parvani JG, Schiemann WP. The pathophysiology of epithelialmesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia 2010; 15: 169-190.
37. Kolosova I, Nethery D, Kern JA. Role of Smad2/3 and p38 MAP kinase in TGFbeta1- induced epithelial-mesenchymal transition of pulmonary epithelial cells. J Cell Physiol 2011; 226: 1248-1254.
38. Bokobza SM, Ye L, Kynaston H, Jiang WG. Growth and differentiation factor 9 (GDF-9) induces epithelial-mesenchymal transition in prostate cancer cells. Mol Cell Biochem 2011; 349: 33-40.
39. Schier AF. Nodal morphogens. Cold Spring Harb Perspect Biol 2009; 1: a003459.
40. Kelber JA, Panopoulos AD, Shani G, Booker EC, Belmonte JC, Vale WW et al. Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways. Oncogene 2009; 28: 2324-2336.
41. Kannan S, De SM, Lohmeyer M, Riese DJ, Smith GH, Hynes N et al. Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells. J Biol Chem 1997; 272: 3330-3335.
42. Strizzi L, Bianco C, Normanno N, Seno M, Wechselberger C, Wallace-Jones B et al. Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Cripto-1 transgenic mice. J Cell Physiol 2004; 201: 266-276.
43. Rangel MC, Karasawa H, Castro NP, Nagaoka T, Salomon DS, Bianco C. Role of Cripto-1 during epithelial-to-mesenchymal transition in development and cancer. Am J Pathol 2012; 180: 2188-2200.
44. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000; 1: 169-178.
45. Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, Moses HL. Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia 2004; 6: 603-610.
46. Li Q, Mattingly RR. Restoration of E-cadherin cell-cell junctions requires both expression of E-cadherin and suppression of ERK MAP kinase activation in Rastransformed breast epithelial cells. Neoplasia 2008; 10: 1444-1458.
47. Tabaries S, Dong Z, Annis MG, Omeroglu A, Pepin F, Ouellet V et al. Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. Oncogene 2011; 30: 1318-1328.